Krishna Institute of Medical Sciences reported a 35.3% year-on-year surge in consolidated revenue from operations to ₹1,180 crore for the quarter ended June 30, 2026 (Q1FY27), driven by robust patient volume growth and the integration of new hospital assets. Consolidated net profit attributable to owners declined to ₹41.50 crore from ₹78.60 crore in the same period last year, reflecting higher operational costs from ongoing expansion. EBITDA stood at ₹220 crore, with EBITDA margin contracting to 18.94% from 22.10% year-on-year. The Board of Directors approved the unaudited financial results on August 3, 2026.

Financial Performance Highlights

The company's total income reached ₹1,196 crore, marking a 36.1% increase year-on-year and a 10.3% rise quarter-on-quarter. Profit before tax (PBT) fell 50.2% year-on-year to ₹57 crore, impacted by statutory adjustments related to new Labour Codes and fair valuation losses on call options. Basic earnings per share (EPS) degrew by 47.2% to ₹1.04. The following table summarises key financial metrics across comparable periods:

Operational Growth and Volume Metrics

Patient volumes were the primary driver of top-line growth. Inpatient (IP) admissions rose 26.6% year-on-year to 72,493, while outpatient (OP) visits increased 28.5% to 658,617. Average Revenue Per Occupied Bed (ARPOB) increased 9.7% year-on-year to ₹47,200. Average Revenue Per Patient (ARPP) rose 6.8% year-on-year to ₹1,63,573, though it declined 3.8% quarter-on-quarter. The group's bed capacity expanded to over 8,300 beds across 26 hospitals, with plans to add more than 1,300 beds in upcoming projects.

New O&M and Strategic Agreements

Krishna Institute of Medical Sciences signed Operations & Management (O&M) and Call Option Agreements with Golden Lan and Sarwottam Healthcare, marking further steps in its asset-light expansion strategy. These agreements are consistent with the group's approach of managing hospital facilities under O&M arrangements while retaining the option to acquire ownership stakes at a future date. The addition of these partnerships is expected to broaden the group's geographic footprint and contribute to revenue ramp-up over time.

Regional Performance and Clinical Milestones

Telangana remained the largest revenue contributor. Newer markets showed early traction: Kerala units generated revenue with an EBITDA margin of 9.7%, while Maharashtra units posted an EBITDA margin of 7.5%. Karnataka units continued to face headwinds. Clinically, KIMS Secunderabad completed 10,000 brain tumour surgeries. KIMS Kingsway Nagpur performed its first allogeneic bone marrow transplant and the first robotic Perceval plus valve implantation in Asia Pacific. KIMS Saveera Anantapur achieved the region's first Transcatheter Aortic Valve Replacement (TAVR).

What the Numbers Show

The divergence between robust revenue growth and declining net profit highlights the capital-intensive nature of KIMS' expansion strategy. While EBITDA growth confirms operational activity in core units, the bottom line is pressured by initial setup costs, higher finance expenses, EBITDA margin compression, and non-controlling interest impacts in newly acquired facilities. The ramp-up of O&M units, including the newly signed agreements with Golden Lan and Sarwottam Healthcare, suggests improving returns on recent investments as occupancy rates stabilise.

Krishna Institute of Medical Sciences Limited has utilized ₹1,084 crore of its ₹1,500 crore Qualified Institutional Placement (QIP) proceeds in the quarter ended June 30, 2026. The healthcare company directed the bulk of these funds toward debt reduction, fully repaying ₹910 crore of its own outstanding borrowings and deploying ₹130 crore toward subsidiary debt repayments. This rapid deployment marks significant progress against the placement document’s objective to utilize net proceeds of ₹1,476.45 crore by FY27.

The monitoring agency report, issued by CARE Ratings Limited on August 3, 2026, was reviewed by the Audit Committee of Krishna Institute of Medical Sciences Limited. The filing was submitted pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 162A(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Pritesh Rath, Associate Director at CARE Ratings, served as the authorized signatory for the report.

Fund Utilization Breakdown

The company allocated its initial utilization primarily to balance sheet optimization. The following table details the deployment of funds across various objects during Q1FY27:

Of the ₹130 crore utilized for subsidiary investments, ₹100 crore was deployed for Chalasani Hospitals Pvt Ltd and ₹30 crore for KIMS Hospital Bengaluru Pvt Ltd. The remaining ₹85 crore allocated for subsidiary debt repayment remains unutilized as of June 30, 2026.

General Corporate Purposes and Commingling

For General Corporate Purposes (GCP), the company utilized ₹44 crore. This included ₹22 crore for salaries and consultants, ₹20 crore invested in KIMS Hospital Bengaluru Private Limited, and ₹2 crore in Chalasani Hospitals. CARE Ratings noted a material disclosure regarding fund management: proceeds designated for GCP were transferred to the company’s and subsidiaries’ current accounts. Because these accounts are used for routine business transactions, the monitored proceeds were commingled with regular business funds. The monitoring agency highlighted this structure in its report, noting that while permissible under certain conditions, it reduces the visibility of specific fund tracking compared to segregated accounts.

Deployment of Unutilized Proceeds

As of June 30, 2026, ₹413.51 crore remained unutilized. In line with SEBI regulations allowing temporary investment in creditworthy instruments, the company deployed ₹360 crore into ICICI Prudential Mutual Funds. The remaining balance was held in bank accounts maintained with Kotak Mahindra Bank.

What the Numbers Show

The immediate and full repayment of ₹910 crore in parent company borrowings signals a strategic priority on deleveraging rather than operational expansion in the first quarter. While this strengthens the balance sheet, the commingling of GCP funds with routine operating accounts introduces a layer of complexity for investors tracking the precise utilization of capital raised. The retention of over ₹400 crore in low-risk liquid instruments suggests the company is maintaining liquidity buffers before committing to further long-term expenditures or subsidiary investments in subsequent quarters.